These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM; PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial. Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ; JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703 [TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy. Mavroudis PD; van den Anker J; Conklin LS; Damsker JM; Hoffman EP; Nagaraju K; Clemens PR; Jusko WJ J Clin Pharmacol; 2019 Jul; 59(7):979-988. PubMed ID: 30742306 [TBL] [Abstract][Full Text] [Related]
5. Assessing Pharmacogenomic loci Associated with the Pharmacokinetics of Vamorolone in Boys with Duchenne Muscular Dystrophy. Li X; Sabbatini D; Pegoraro E; Bello L; Clemens P; Guglieri M; van den Anker J; Damsker J; McCall J; Dang UJ; Hoffman EP; Jusko WJ J Clin Pharmacol; 2024 Sep; 64(9):1130-1140. PubMed ID: 38682893 [TBL] [Abstract][Full Text] [Related]
6. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models. Liu G; Lipari P; Mollin A; Jung S; Teplova I; Li W; Ying L; More V; Lennox W; Yeh S; McGann E; Moon YC; Rice C; Huarte E; Gruszka B; Ray B; Goodwin E; Buckendahl P; Yurkow E; Braughton B; Narasimhan J; Welch E; Voronin G; Weetall M Hum Mol Genet; 2024 Jan; 33(3):211-223. PubMed ID: 37819629 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925 [TBL] [Abstract][Full Text] [Related]
8. Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy. Grounds MD; Lloyd EM J Neuromuscul Dis; 2023; 10(6):1013-1030. PubMed ID: 37927274 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial. Dang UJ; Damsker JM; Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans NM; Haberlová J; Straub V; Mengle-Gaw L; Schwartz BD; Harper A; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster RI; Mcmillan HJ; Kuntz N; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez JJ; Nascimento-Osorio A; Niks EH; De Groot IJM; Katsalouli M; Van Den Anker JN; Ward LM; Leinonen M; D'Alessandro AL; Hoffman EP Neurology; 2024 Mar; 102(5):e208112. PubMed ID: 38335499 [TBL] [Abstract][Full Text] [Related]
10. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Conklin LS; Damsker JM; Hoffman EP; Jusko WJ; Mavroudis PD; Schwartz BD; Mengle-Gaw LJ; Smith EC; Mah JK; Guglieri M; Nevo Y; Kuntz N; McDonald CM; Tulinius M; Ryan MM; Webster R; Castro D; Finkel RS; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; McCall JM; Hathout Y; Nagaraju K; van den Anker J; Ward LM; Ahmet A; Cornish MR; Clemens PR Pharmacol Res; 2018 Oct; 136():140-150. PubMed ID: 30219580 [TBL] [Abstract][Full Text] [Related]
11. Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy. Li X; Conklin LS; van den Anker J; Hoffman EP; Clemens PR; Jusko WJ J Clin Pharmacol; 2020 Oct; 60(10):1385-1396. PubMed ID: 32434278 [TBL] [Abstract][Full Text] [Related]
12. Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. Liu X; Wang Y; Gutierrez JS; Damsker JM; Nagaraju K; Hoffman EP; Ortlund EA Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24285-24293. PubMed ID: 32917814 [TBL] [Abstract][Full Text] [Related]
13. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Hoffman EP; Schwartz BD; Mengle-Gaw LJ; Smith EC; Castro D; Mah JK; McDonald CM; Kuntz NL; Finkel RS; Guglieri M; Bushby K; Tulinius M; Nevo Y; Ryan MM; Webster R; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Siener C; Jaros M; Shale P; McCall JM; Nagaraju K; van den Anker J; Conklin LS; Cnaan A; Gordish-Dressman H; Damsker JM; Clemens PR; Neurology; 2019 Sep; 93(13):e1312-e1323. PubMed ID: 31451516 [TBL] [Abstract][Full Text] [Related]
14. Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better? Kourakis S; Timpani CA; Campelj DG; Hafner P; Gueven N; Fischer D; Rybalka E Orphanet J Rare Dis; 2021 Mar; 16(1):117. PubMed ID: 33663533 [TBL] [Abstract][Full Text] [Related]
15. Givinostat: First Approval. Lamb YN Drugs; 2024 Jul; 84(7):849-856. PubMed ID: 38967716 [TBL] [Abstract][Full Text] [Related]